NCT04541537 (KDOG COV) is a NA clinical trial of Sorbstar® in Breast Cancer, sponsored by Institut Curie.

Who is sponsoring NCT04541537?

NCT04541537 is sponsored by Institut Curie.

What drugs are being tested in NCT04541537?

Interventions in NCT04541537: Sorbstar®, Dog Detection.

What condition does NCT04541537 study?

NCT04541537 studies Breast Cancer, Surgery.

Is NCT04541537 still recruiting?

NCT04541537 is currently completed. Last updated 22 September 2025.

Last reviewed 2025-09-22 · How we verify

NCT04541537: KDOG COV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer. (KDOGCOV)

Completed NA Last updated 22 September 2025

What this trial tests

NA trial testing Sorbstar® in Breast Cancer in 35 participants. Completed in 20 December 2021.

Timeline

25 January 2021

Primary endpoint
9 December 2021

20 December 2021

Quick facts

Lead sponsor	Institut Curie
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	triple
Primary purpose	diagnostic
Enrollment	35
Start date	25 January 2021
Primary completion	9 December 2021
Estimated completion	20 December 2021
Sites	1 location across France

Drugs / interventions tested

Sorbstar®
Dog Detection

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Surgery — all drugs for Surgery →

Sponsor

Institut Curie — full company profile →

Who can join

18 and older, female only, with Breast Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To ascertain the possibilities to isolate the breast cancer olfactive signature

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Screening of Breast Cancer from Sweat Samples Analyzed by 2-Dimensional Gas Chromatography-Mass Spectrometry: A Preliminary Study.
Leemans M, Cuzuel V, Bauër P, Baba Aissa H, et al · · 2023 · cited 9× · PMID 37296901 · DOI 10.3390/cancers15112939

Verify or expand the search:

Other trials of Sorbstar®

Trials testing the same drug.

NCT03703557 — Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer · NA · completed

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Institut Curie trials

Trials by the same sponsor.

NCT07357948 — Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy · NA · not yet recruiting
NCT07491380 — Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TD · NA · not yet recruiting
NCT07193394 — Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer · Phase 2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
NCT06659705 — Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04541537 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Curie
Last refreshed: 22 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04541537.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing